BCV Asset Management’s Gossamer Bio GOSS Stock Holding History

BCV Asset Management’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.5K	Hold	106,500	–	–	﹤0.01%	116
2026 Q1	$35K	Buy	+106,500	New	+$167K	﹤0.01%	119

Other funds holding GOSS

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

DIG

DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

BCV Asset Management's GOSS Position: Q2 2026 in Review

BCV Asset Management held its Gossamer Bio (GOSS) position steady in Q2 2026 at 106,500 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #116.

BCV Asset Management first reported a position in GOSS in Q1 2026 and has held it in 2 quarters since. The position peaked at $35K in Q1 2026. 170 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

BCV Asset Management held 106,500 shares of Gossamer Bio worth $17.5K as of Q2 2026.
BCV Asset Management left its Gossamer Bio share count unchanged in Q2 2026.
Gossamer Bio made up ﹤0.01% of BCV Asset Management's portfolio in Q2 2026, its #116 holding.
BCV Asset Management first reported a position in Gossamer Bio in Q1 2026 and has held it in 2 quarters since.
BCV Asset Management's Gossamer Bio position peaked at $35K in Q1 2026.
170 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on BCV Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.